Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib roll-over study for long-term safety in Ph+ CML and Ph+ ALL
jRCT2051240084Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Open-label trial of asciminib in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Novartis. Primary endpoint: Long-term safety of asciminib treatment. Started Dec 2022; status: active, not recruiting.
02
Drugs
asciminib
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT2051240084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240084.